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funded programs like Medicaid. Objective of this study was to
review published studies that evaluate the impact of Medicaid
formularies, and to assess the perspective that was adopted 
for such evaluations. METHODS: Searches were performed in
several scientiﬁc and business databases along with other rele-
vant health policy journals and websites. The search strategy
involved an incremental focus using a tiered approach, narrow-
ing search returns down to the speciﬁc inclusion criteria with
multiple combinations of search terms. Selected articles were
reviewed to assess the perspective adopted based on key mea-
surement parameters used in evaluation of the impact.
RESULTS: Twenty studies were selected for the review. All
studies used a pre-post or a time-series research design. Three
studies utilized pooled multi-state data, two studies included a
second state’s Medicaid population as a control group, and the
remaining were studies of single state Medicaid populations. 
All studies evaluated direct impacts of a formulary strategy on
drug and program costs. Three studies additionally investigated
broader second order effects on physician, outpatient and hos-
pital utilization. None of the evaluations included estimates of
indirect costs related to the positive or negative impact of for-
mularies on morbidity, mortality and consequent productivity of
Medicaid beneﬁciaries. Therefore, the true impact of formularies
in these evaluations remain unclear. CONCLUSION: Findings of
the literature review of Medicaid formulary evaluations suggest
that such a societal perspective has not been widely adopted, and
can be a valuable option for future evaluations.
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OBJECTIVE: There is an increasing interest in pharmacoeco-
nomics among physicians. However, as can be seen from multi-
ple examples, the concept is prone for abuse and misuse. In this
study we evaluated the curriculum of the Turkish medical
schools. We looked at whether they have any formal pharma-
coeconomic lectures or they are planning on introducing phar-
macoecononmics lectures within the pharmacology, clinical
pharmacology or other courses. METHODS: A questionnaire
was prepared to evaluate the pharmacoeconomics education at
35 Medical Schools in Turkey. We got in contact with the head
of the Pharmacology Departments either by phone or by face to
face interviews. The questionnaire was composed of questions
regarding the presence of pharmacoeconomics lectures; i.e. if
already in curriculum, at which year, and for how many hours.
If no pharmacoeconomics lecture exists, is there any intention of
including it in the curriculum. RESULTS: We got replies from 27
(77%) of the Pharmacology Departments. Pharmacoeconomy
lecture is currently given only at two niversities (Ankara,
Atatürk). All but two of the other departments communicated
that pharmacoeconomics lectures will be given in the future.
CONCLUSION: Pharmacoeconomics is an important part of
clinical pharmacology. However the concept is not part of the
medical school curriculum in most universities. There is a trend
towards giving pharmacoeconomics classes at fourth or ﬁfth year
within clinical pharmacology lectures. Even though most of the
pharmacology departments informed that they are going to
include pharmacoeconomics into the curriculum, currently prac-
ticing physicians lack the necessary knowledge. In our opinion,
in addition to the inclusion of pharmacoeconomics in the
medical school curriculums, special programs are also required
for physicians who had not had a formal pharmacoeconomic
course during their undergraduate education. There is an increas-
ing responsibility for pharmacology/clinical pharmacology
departments to take a role in such programs.
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OBJECTIVE: Industrial organization economics theory sug-
gested ﬁrms may over- or under-advertise to deter or accommo-
date entry depending on how advertising affects the proﬁts of
competitors, and if the competing products are strategic substi-
tutes or complements. The objective of this study was to deter-
mine if this theory holds for pharmaceutical products. Such
information would increase policy makers’ understanding of
how advertising affects competition when considering advertis-
ing regulations. METHODS: Data on products for eight therapy
areas (asthma, migraine, obesity, Parkinson’s disease, seizure,
depression, dyslipidemia, and gastric and duodenal ulcer) from
January, 1995 to December, 2001 were analyzed on a quarterly
basis. Multivariate analyses were performed to examine the
strategic relationship between advertising expenditures and
product sales. Changes in an existing product’s advertising
expenditure in the period after new product entry were exam-
ined using time-disease ﬁxed-effects regression, by controlling for
the type of new entrants (the presence of creative entrants, uncre-
ative entrants or both in the same period), patent life, and market
share. Creative entrants were new products with novel pharma-
cological mechanisms of action that were different from that of
existing products. Uncreative entrants included me-too drugs
and generic products. Advertising expenditure and sales data
were obtained from Scott-Levin Market Research Audit. Patent
and product entry information were from published references.
RESULTS: Multivariate analyses showed competing pharma-
ceutical products were strategic complements and sales of new
entrants increased with existing product’s advertising expendi-
ture, although these relationships were not statistically signiﬁ-
cant. There were no statistically signiﬁcant changes in advertising
expenditure in response to any types of new product entry. CON-
CLUSION: The strategic effect of advertising on market com-
petitiveness was weak and not signiﬁcant. No evidence was
found that pharmaceutical ﬁrms would use advertising as a
strategic tool to deter or accommodate entry. These results did
not support regulating pharmaceutical advertising based on anti-
competitive grounds.
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OBJECTIVES: To model the effect of mail order vs. community
pharmacy on drug utilization and drug product cost in a 
Medicaid population. METHODS: Drug treatments initiated
between August, 2000 and July, 2001 were retrieved. Drug treat-
ments with at least two claims and 60 days of supply, and an
adherence ratio of 0.5 were included in the study. In the base-
line scenario, utilization in mail order was modeled using the uti-
lization in community pharmacy, and assuming that the ﬁrst
prescription was dispensed in community pharmacy, and suc-
cessive prescriptions were dispensed as 90-day supply in mail
